Pharmacia Biotech (Sweden) and Corning Nichols Institute (US) look at p53 in breast cancer
This article was originally published in Clinica
Executive Summary
Pharmacia Biotech (Sweden) and the Corning Nichols Institute (US) are investigating the prognostic value of p53 in breast tumours. The collaborative project will look at the correlation between nucleic acid sequence-based diagnosis and immunohistochemistry and will then go on to look at the link between p53 mutation and clinical outcome for breast cancer patients.